Over a fouryear period children aged 2 years and above who received VOXZOGO exhibited a mean average height Zscore improvement of 11 to 14 standard deviations 95 CI limits from 046 to 193 and a mean height gain of 63 to 78 centimeters cm 95 CI limits from 298 to 1040 cm when compared to untreated children with achondroplasia of the same age and sex